Business ❯ Pharmaceutical Industry ❯ Market Competition

Drug Pricing

Novo Nordisk Cost Analysis Insurance Coverage Consumer Health Weight Loss Solutions Compounded Drugs Access to Medication Eli Lilly Novo Nordisk's Semaglutide Patent Issues Merck Market Dominance

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

Merck plans to seek FDA review in early 2026 based on these Phase 3 lipid-lowering results.